However, these inhibitors targeting KRAS G12C mutations fail to achieve the ideal objective response in CRC patients, and the patients who respond early to inhibitors of KRAS G12C mutations quickly develop drug resistance [52]. The gene discussed is KRAS; the disease is colorectal carcinoma.